A5055367355- Gastrointestinal Tumor Research and Treatment
- Sarcoma Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Gastrointestinal disorders and treatments
- Health Systems, Economic Evaluations, Quality of Life
- Colorectal and Anal Carcinomas
- Metastasis and carcinoma case studies
- Vascular Tumors and Angiosarcomas
- Cancer Diagnosis and Treatment
- Cardiac tumors and thrombi
- Frailty in Older Adults
- Platelet Disorders and Treatments
- Genetic factors in colorectal cancer
- Estrogen and related hormone effects
- Neuroendocrine Tumor Research Advances
- Nutrition and Health in Aging
- Soft tissue tumor case studies
- Neurofibromatosis and Schwannoma Cases
- Oral and Maxillofacial Pathology
- Thyroid Cancer Diagnosis and Treatment
- Cancer survivorship and care
- Cancer Immunotherapy and Biomarkers
Ospedale Policlinico San Martino
2010-2025
University of Genoa
2004-2007
Novartis (Italy)
2004
Italian Association for Cancer Research
2004
Alleanza Contro il Cancro
1996-2001
Medica (Italy)
2000
Ospedali Riuniti Umberto I
1999
In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). This analysis characterises the association of PFS CRC symptoms, health-related quality life (HRQoL), and overall (OS). symptoms (NCCN/FACT symptom index, FCSI) HRQoL (EQ-5D) were assessed for 207 184 best supportive care (BSC) who had at least one post-baseline patient-reported outcome (PRO) assessment. Patients alive week 8...
Background: Gastrointestinal stromal tumors (GIST) are known to carry oncogenic KIT or PDGFRA mutations, less commonly SDH NF1 gene inactivation, with very rare cases harboring mutant BRAF RAS alleles. Approximately 10% of GISTs devoid any such mutations and characterized by limited therapeutic opportunities poor response standard treatments. Methods: Twenty-six sporadic KIT/PDGFRA/SDH/RAS-pathway wild type GIST were profiled for the molecular status genes frequently altered in a targeted...
Inflammatory myofibroblastic tumor (IMT) is a very rare subtype of sarcoma, which frequently harbor chromosomal rearrangements, including anaplastic lymphoma kinase (ALK) rearrangements (almost 50% the IMTs) and other fusions such as ROS1. ROS1 are present in about 10% IMT, almost half ALK-negative IMT patients. Apart from radical surgery for resectable tumors, there no standard-of-care therapy advanced IMTs. Nonetheless, use tyrosine inhibitors has shown promising efficacy patients with...
Angiosarcoma (AS) represents a rare and aggressive vascular sarcoma, posing distinct challenges in clinical management compared to other sarcomas. While the current European Society of Medical Oncology (ESMO) practice guidelines for sarcoma treatment are applicable AS, its unique aggressiveness diverse tumor presentations necessitate dedicated detailed recommendations, which currently lacking. Notably, considerations regarding surgical extent, radiation therapy (RT), neoadjuvant/adjuvant...
Background Although elderly patients (≥70 years) represent 30% of new diagnoses soft tissue sarcoma (STS), they are underrepresented in clinical trials and often unfit to receive standard anthracycline‐based chemotherapy. Trabectedin is registered as a second‐line treatment for advanced STS characterized by favorable safety profile. Methods The aim this single‐arm, phase 2 study was investigate trabectedin (scheduled dose, 1.3‐1.5 mg/m ) first‐line with stage who inoperable coprimary...
asparagine-glycine-arginine-human tumour necrosis factor (NGR-hTNF), an agent selectively damaging the vasculature, showed a biphasic dose-response curve in preclinical models. Previous phase I trials of NGR-hTNF indicated 0.8 and 45 μg/m(2) as optimal biological maximum-tolerated dose, respectively.Two sequential cohorts 12 colorectal cancer (CRC) patients who had failed standard therapies received or combination with capecitabine-oxaliplatin (XELOX).Median number prior treatment lines was...
Importance Gastrointestinal stromal tumor (GIST) follow-up is recommended by international guidelines, but data on the role of in patients with low relapse risk are missing. For these patients, potential benefit anticipating recurrence detection should be weighed against psychological burden and radiologic examination loads terms costs radiation exposure. Objective To evaluate outcomes guideline-based low-risk GIST. Design, Setting, Participants This multi-institutional retrospective cohort...
Tenosynovial giant cell tumour (TGCT) is a group of rare soft tissues neoplasia affecting synovial joints, bursae and tendon sheaths classified as localized type or diffuse type. The (TGCT-D), also known ‘pigmented villonodular (teno)synovitis’ characterized by local aggressivity, with invasion destruction adjacent soft-tissue structures, high recurrence rate. Radical surgery remains the standard therapy while adjuvant radiotherapy may help to control spread. Malignant TGCT rate recurrences...
Gastrointestinal stromal tumors (GISTs) are rare neoplasms, but they also represent the most common mesenchymal of gastrointestinal tract originating from cell Cajal. GIST incidence ranges around 1% all malignancies. Approximately 5% GISTs have a hereditary etiology. The remaining 95% considered sporadic events, with up to 75% cases driven by constitutional activation c-KIT proto-oncogene. generally solitary lesions. Nonetheless, multiple can occur and present as synchronous or metachronous...
9028 Background: As from the first patients treated in 2000–2001, Imatinib mesylate was shown to be highly effective advanced GIST, but patterns of tumor response were seen peculiar. Methods: From March December 2002, 135 Italian with metastatic and/or locally advanced, inoperable, KIT-positive GIST entered a prospective clinical study on best use mesylate, organized by Novartis Pharma cooperation Sarcoma Group. A total 129 evaluable for at 9 months. Median age is 65 yrs; M:F ratio 70:59;...
Abstract Mitotic count (MC) is an important prognostic indicator in gastrointestinal stromal tumours (GISTs). Though MC evaluation was initially proposed 50 HPFs, recent international guidelines recommend that be performed on 5 mm 2 because HPFs may have different areas depending the ocular field number (FN) of utilized light microscope. Performing leads to a non-standardized and erroneous risk stratification. The aim study audit real-life practices with special emphasis possible...
9028 Background: As from the first patients treated in 2000–2001, Imatinib mesylate was shown to be highly effective advanced GIST, but patterns of tumor response were seen peculiar. Methods: From March December 2002, 135 Italian with metastatic and/or locally advanced, inoperable, KIT-positive GIST entered a prospective clinical study on best use mesylate, organized by Novartis Pharma cooperation Sarcoma Group. A total 129 evaluable for at 9 months. Median age is 65 yrs; M:F ratio 70:59;...
In the post-Imatinib era, median survival of patients diagnosed with GIST has reached almost 5 years.Prolonging GIST-specific survival, have an increased incidence secondary neoplasia.Data on prognostic impact second tumors in are very poor few and small retrospective analyses available literature.We conducted a monocentric analysis 145 between April 2001 October 2018.Kaplan-Meier Cox hazard methods were used for analysis.A total 154 included 31 them (21%) at least one additional...